| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$4 |
FY25 Full Year Results Presentation and Update
|
29 Aug 2025 8:25AM |
$0.105 |
$0.041 |
fallen by
60.95%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Acquired Inhouse Ventures and Tank Stream Labs.
- Services revenue increased by 78% to $2.9 million.
- Supporting over 850 founders across various programs.
- Strategic focus on early-stage tech startups.
- Significant investments in Regtech, Fintech, and Medtech.
- Gross profit of $1.74 million and a net loss of $2.64 million.
- Ongoing growth through strategic acquisitions and partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$4 |
FY25 Appendix 4E and Annual Report
|
29 Aug 2025 8:25AM |
$0.105 |
$0.041 |
fallen by
60.95%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Scalare Partners Holdings Limited underwent a reverse acquisition by Scalare Partners Pty Ltd.
- Financial statements consolidate Scalare Partners Pty Ltd and Scalare Partners Holdings Limited as of June 2025.
- Issued capital increased significantly from $7,889,530 in 2024 to $13,544,378 in 2025.
- The company reported a loss of $2,645,490 for FY25.
- Revenue grew from $2.81 million in 2024 to $3.54 million in 2025.
- The report details the acquisition of Tech Ready Women Pty Ltd and InHouse Ventures Pty Ltd.
- The consolidation led to an increased share issuance and capital management activities.
- Financial assets at fair value increased from 2024 to 2025.
- Equity holders are informed about share-related details and substantial shareholders as of July 2025.
- Listed on the Australian Securities Exchange under ticker code SCP.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$4 |
FY25 Appendix 4E and Annual Report
|
29 Aug 2025 8:25AM |
$0.105 |
$0.041 |
fallen by
60.95%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Scalare Partners Holdings Limited had a reverse acquisition by Scalare Partners Pty Ltd.
- For the financial year ending June 30, 2025, Scalare Partners Holdings reported a total net asset of AUD 13,434,042.
- The company's operating segment now includes operations in the USA as of February 2025.
- Scalare Partners Holdings Limited is listed on the Australian Securities Exchange under ticker SCP.
- The company issued 5,867,756 new shares and incurred a cost of AUD 212,908 in the process.
- A net loss of AUD 2,645,490 was recorded for the year ending June 30, 2025.
- Major financial assets include options, shares, and convertible notes totaling AUD 11,232,975.
- Scalare Partners Holdings Limited's equity increased due to the issue of shares and share-based payments.
- Key management personnel received a total remuneration of AUD 2,275,941 for 2025.
- The Annual General Meeting is scheduled for November 27, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
FY25 Results Announcement
|
29 Aug 2025 8:24AM |
$3.940 |
$0.410 |
fallen by
89.59%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory NPAT increased by 117.0% to $28.1M.
- Pro-forma revenue decreased by 1.5% to $1,943.5M.
- Significant items post-tax amounted to $52.3M, mostly non-cash.
- Positive free cash flow generation improved by $31.0M over FY24.
- Cash conversion improved to 81.8% from 76.9% in FY24.
- Refinanced $170M of debt, with available liquidity over $340M.
- Final dividend of 5.5cps, total FY25 dividend of 13.5cps.
- Strategic focus on simplifying operations and reducing costs.
- Closure and relocation of 70 sites caused operational disruption.
- Investments in IT infrastructure and systems.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
FY25 Results Announcement
|
29 Aug 2025 8:24AM |
$3.940 |
$0.410 |
fallen by
89.59%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory NPAT of $28.1M, up 117.0% from FY24.
- Pro-forma group revenue of $1,943.5M, down 1.5% from FY24.
- Pro-forma EBITDA of $246.7M, down 4.1% from FY24.
- Trade segment revenue up 1.3% and EBITDA up 5.4%.
- Specialist Wholesale revenue down 3.2% while EBITDA improved by 5.2%.
- Continued challenging conditions in Retail and New Zealand segments.
- Strategic re-set focusing on simplifying operations and cost reduction.
- Investments in IT infrastructure and achieving $27.5M in cost savings.
- Positive free cash flow and a strong balance sheet.
- Final dividend of 5.5cps, total FY25 dividend of 13.5cps.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$77 |
AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
|
29 Aug 2025 8:24AM |
$0.170 |
$0.150 |
fallen by
11.76%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
Appendix 4G
|
29 Aug 2025 8:24AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$28 |
Change of Director's Interest Notice - S Evans
|
29 Aug 2025 8:24AM |
$0.370 |
$0.385 |
risen by
4.05%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
NOL Corporate Governance Statement
|
29 Aug 2025 8:24AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,667 |
Preliminary Final Report including Appendix 4E
|
29 Aug 2025 8:23AM |
$2.420 |
$2.060 |
fallen by
14.88%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Preliminary Final Report for the financial year ending June 30, 2024.
- Includes Appendix 4E detailing financial performance.
- Covers revenue, expenses, and net loss figures.
- Discusses strategic initiatives and clinical program progress.
- Focus on development and regulatory progress of remestemcel-L.
- Details on share-based payments and equity changes.
- Overview of financial position and cash flow.
- Impact of external factors on operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
NobleOak FY25 Results Presentation
|
29 Aug 2025 8:23AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- NobleOak Life Limited reported a strong financial performance for FY25, with a 20% increase in in-force premiums, reaching $464.2 million.
- The company achieved a statutory net profit after tax (NPAT) of $7.1 million, impacted by economic assumptions and other non-recurring costs.
- NobleOak exhibited disciplined insurance risk management, leading to improved insurance margins.
- A significant growth in market share was observed, now holding 4.1% of the individual life risk market.
- The company continues to transition to a Life Company structure, aiming for long-term capital efficiency and governance improvements.
- NobleOak's Embedded Value (EV) increased by 90% since IPO, reflecting strong growth potential.
- The company is leveraging AI and automation to enhance customer experience and operational efficiency.
- NobleOak was named Life Insurance Company of the Year 2025 by the Australian and New Zealand Institute of Insurance and Finance.
- The company plans a strategic focus on expanding digital platforms and entering new product adjacencies to drive growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
FY25 Appendix 4E and Financial Report
|
29 Aug 2025 8:23AM |
$3.940 |
$0.410 |
fallen by
89.59%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after income tax of $28,225,000.
- Total revenue of $1,975,767,000.
- Significant recovery from a prior year loss of $165,717,000.
- Major revenue contribution from Bapcor Trade segment.
- Key financial impacts include asset write-offs and restructuring.
- Total assets at $1,827,122,000 and total equity at $855,853,000.
- Focus on employee equity plans and share-based payments.
- Efforts on efficient capital allocation to enhance shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
NobleOak FY25 Results Presentation
|
29 Aug 2025 8:23AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong in-force premium growth and margin expansion.
- Statutory profit of $7.1 million with 52% NPAT growth.
- Transitioning to a Life Company structure for better capital efficiency.
- Continued market share growth driven by digital investment.
- Robust capital position with a capital adequacy multiple of 186%.
- Strategic acquisition of RevTech aids in margin expansion.
- Investment in AI and digital platforms for enhanced market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
FY25 Appendix 4E and Financial Report
|
29 Aug 2025 8:23AM |
$3.940 |
$0.410 |
fallen by
89.59%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidation of warehouses and change in inventory costing policy
- Retrospective financial adjustments for prior periods
- Segment performance with total consolidated revenue of $1,975,767,000
- Detailed long-term incentive plans for executives
- Performance metrics include Return on Invested Capital and Total Shareholder Return
- FY25 ended with total equity of $855,853,000
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$23 |
Change of Director's Interest Notice - S Evans
|
29 Aug 2025 8:22AM |
$0.565 |
$0.510 |
fallen by
9.73%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
NobleOak FY25 Results Release
|
29 Aug 2025 8:22AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- In-force premiums grew 20% to $464.2 million as of 30 June 2025.
- Underlying NPAT increased by 22% to $18.3 million.
- Statutory NPAT reduced by 23% to $7.1 million due to provisions and economic changes.
- Embedded Value published at $197.6 million, reflecting strong growth trajectory.
- Transition to a Life Company structure to enhance capital efficiency.
- New partnerships and products to drive future growth.
- FY26 targets include over 15% growth in in-force premiums and over 10% growth in NPAT.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
NobleOak FY25 Results Release
|
29 Aug 2025 8:22AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- In-force premium grew by 20% to $464.2 million.
- Market share increased to 4.1%.
- Underlying NPAT rose by 22% to $18.3 million.
- Statutory NPAT dropped by 23% to $7.1 million.
- Strong partnerships and new product launches planned.
- Transition to a Life Company to improve capital efficiency.
- FY26 targets over 15% in-force premium growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$111 |
Preliminary Final Report
|
29 Aug 2025 8:22AM |
$0.215 |
$0.375 |
risen by
74.42%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Income from ordinary activities decreased by 86% to $177,711.
- Net loss after tax increased by 36.9% to $3,920,139.
- No dividends were paid, declared, or recommended.
- Net tangible assets per ordinary security rose to 3.03 cents.
- The financial statements received an unmodified audit opinion.
- No changes in control over entities.
- Report signed by Jason Carroll on 29 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$111 |
Preliminary Final Report
|
29 Aug 2025 8:22AM |
$0.215 |
$0.375 |
risen by
74.42%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Income from ordinary activities decreased by 86% to $177,711.
- Loss after tax increased by 36.9% to $3,920,139.
- No dividends were declared or paid during the period.
- Net tangible assets per ordinary security increased to 3.03 cents.
- The financial statements received an unmodified audit opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$46 |
Change of Director's Interest Notice - S Evans
|
29 Aug 2025 8:22AM |
$0.355 |
$0.350 |
fallen by
1.41%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$754 |
Appendix 4G and 2025 Corporate Governance Statement
|
29 Aug 2025 8:22AM |
$2.980 |
$3.620 |
risen by
21.48%
|
|
| Latitude Group Holdings Limited (LFS) ORDINARY FULLY PAID |
Financials |
$957 |
Latitude Financial acknowledges appeal dismissal
|
29 Aug 2025 8:21AM |
$1.150 |
$0.920 |
fallen by
20%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$754 |
Appendix 4E and 2025 Annual Report
|
29 Aug 2025 8:19AM |
$2.980 |
$3.620 |
risen by
21.48%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
FY25 Annual Report
|
29 Aug 2025 8:19AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$116 |
Preliminary Final Report
|
29 Aug 2025 8:19AM |
$1.355 |
$1.245 |
fallen by
8.12%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- NobleOak's capital adequacy remained strong at 186%.
- Underlying NPAT for FY25 was $18.3 million, a 22% increase year-on-year.
- In-force premiums grew by 20% to $464.2 million as of 30 June 2025.
- NobleOak's market share increased to 4.1% as of December 2024.
- Reported NPAT for FY25 was $7.1 million, down 23% from FY24.
- Investment returns increased to $12.8 million pre-fees due to higher interest rates.
- The company's strategic initiatives included a transition to a Life Insurance Company structure.
- No dividends were declared for the current or prior year.
- The administration expense ratio remained stable at 7.2%.
- Operating cash flows improved significantly with net inflows of $58.7 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
